Daybue (Trofinetide) Patent Expiration, LOE Window & CMS Spending

Daybue (Trofinetide) by Acadia Pharmaceuticals: FDA Orange Book core substance LOE 2043-01-12, 0 AB generics, $262.0M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAcadia Pharmaceuticals
FDA Application & PathwayN217026 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2043-01-12
Last Listed Patent or Exclusivity Date2043-01-12
Orange Book Patents (*PED Extensions)8 patents (4 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$262.0M
2024 Medicare Part D Spend$39.6M
2024 Medicaid Spend$222.4M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 16.1% 2-yr change)